Key terms
About TTOO
T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TTOO news
Apr 11
4:08pm ET
T2 Biosystems shareholders vote for CRG debt conversion into equity
Mar 28
4:53pm ET
T2 Biosystems Reinforces Market Position with Extended Vizient Agreement
Mar 28
9:08am ET
T2 Biosystems announces extension of multi-year agreement with Vizient
Mar 20
9:32am ET
T2 Biosystems Anticipates Breakthroughs and Extends NASDAQ Compliance
Mar 20
9:23am ET
T2 Biosystems reiterates 2024 financial outlook
Mar 20
7:37am ET
T2 Biosystems unveils T2Lyme launch plans, business updates
Mar 18
9:23am ET
T2 Biosystems Revolutionizes Infection Detection Efficiency
Mar 18
9:02am ET
T2 Biosystems announces new publication on T2Resistance Panel
Mar 12
9:11am ET
T2 Biosystems receives extension to comply with Nasdaq listing requirement
Feb 15
5:07pm ET
T2 Biosystems’ Strong Financials and Strategic Growth Moves
Feb 15
4:38pm ET
T2 Biosystems announces new territory exclusive distribution agreements
Feb 12
9:03am ET
T2 Biosystems receives FDA clearance for expanded T2Bacteria panel
Jan 18
9:04am ET
T2 Biosystems announces participate in NIJ-funded ARLG pilot study
TTOO Financials
Key terms
Ad Feedback
TTOO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TTOO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
